In Re: National Prescription Opiate Litigation

Track this case

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. October 20, 2026

    Suits Linking Tylenol To Autism, $400M Sandoz Deal And More

    Law360 Healthcare Authority looks at the Second Circuit's denial of a drugmaker's request for full review of expert testimony for plaintiffs in a case alleging Tylenol causes autism, the preliminary approval of a $400 million settlement between Sandoz and a coalition of states in generic drug price-fixing litigation, and other legal news from the past week.

  2. October 15, 2026

    OptumHealth Can't Get Out Of PBM Cases In Opioid MDL

    The healthcare delivery arm of UnitedHealth Group's Optum division can't escape bellwether cases alleging pharmacy benefit managers contributed to the opioid epidemic, an Ohio federal judge ruled Thursday, finding a recent Sixth Circuit decision didn't alter the court's jurisdiction over related state-law claims.

  3. October 02, 2026

    6th Circ. Blocks 100s Of Opioid MDL Cases Targeting PBMs

    The Sixth Circuit on Friday overturned a pivotal decision in multidistrict opioid litigation that had dramatically expanded claims against the nation's largest pharmacy benefit managers, saying the MDL's presiding judge "clearly abused" his authority by belatedly allowing hundreds of new cases in one fell swoop.

  4. September 23, 2026

    Motley Rice Partner Tapped For Opioid Case Co-Lead Counsel

    The Ohio federal judge overseeing multidistrict opioid litigation appointed on Wednesday Donald Migliori, a managing partner at Motley Rice LLC, as co-lead counsel in the wake of the death of the firm's co-founder Joe Rice, who had served in the position for the past eight years.

  5. September 17, 2026

    Opioid MDL Judge Fears 'Chaos' If PBMs Derail 100s Of Suits

    The federal judge steering multidistrict opioid litigation is lacing into major pharmacy benefit managers for asking the Sixth Circuit to abruptly reverse a key ruling, denouncing their "spurious insinuations" about his motives and warning of disarray if they successfully break up the MDL's consolidated suits.

  6. August 27, 2026

    PBMs Hammer Opioid Judge In Last-Ditch Gambit At 6th Circ.

    An Ohio federal judge knowingly flouted a Sixth Circuit rebuke by forcing two of the largest remaining defendants in multidistrict opioid litigation to either "settle for enormous sums or litigate for years hundreds of cases," says a Thursday petition urging the appeals court to intervene.

  7. August 24, 2026

    Tribal Opioid Suits Against Sacklers Slated For $175M Exit

    Dozens of Native American tribes have asked an Ohio federal court to dismiss their lawsuits against members of the Sackler family, which owns bankrupt opioid maker Purdue Pharma, based on a settlement agreement that will pay $175 million to the tribes over 16 years.

  8. July 28, 2026

    J&J $5.5B Talc MDL Deal, $25.4M Cooley Judgment And More

    Law360 Healthcare Authority looks at Johnson & Johnson's $5.5 billion commitment in a proposed settlement to resolve thousands of suits alleging its talcum powder products caused ovarian cancer, a New Jersey state court's order that Cooley LLP pay $25.4 million in litigation over its representation of a biotech founder, and other key resolutions in healthcare litigation over the last week.

  9. July 27, 2026

    Union Funds Seek Final OK For $180M In Opioid Deals

    Union health and welfare funds have asked the Ohio federal judge overseeing the sprawling national opioid litigation to approve settlements totaling $180 million with CVS, Walgreens, Walmart and three pharmaceutical companies to compensate for the costs of opioid use disorder treatment.

  10. October 30, 2025

    Philly Accuses PBMs Of Knowingly Enabling Opioid Crisis

    Philadelphia on Thursday sued CVS Caremark, Express Scripts and Optum, accusing the pharmacy benefit managers of contributing to the city's opioid epidemic via deceptive marketing and conspiring with drugmakers to increase the sale of OxyContin and other prescription opioids.